Sellas Life Sciences shares surge 175% after cancer vaccine succeeds in late-stage trial

Sellas Life Sciences (Nasdaq: SLS) shares rose 175% to $20.54 after its cancer vaccine, galinpepimut-S, met primary goals in a late-stage trial, extending survival in acute myeloid leukaemia patients. The vaccine reduced death risk by 41% and showed median survival of 24 months. Sellas plans to discuss accelerated FDA filing. Results are not yet approved.

Original reporting
Published Nov 17, 2026, 4:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 4:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Sellas Life Sciences shares surge 175% after cancer vaccine succeeds in late-stage trial — source image
Decision brief

The 30-second read

$SLSBullishHigh
01

Why it matters

The pivotal phase 3 readout is a direct valuation catalyst, and the company’s stated plan to meet the FDA about an accelerated filing strategy increases the probability of near-term regulatory momentum.

02

Market read

Traders can reassess probability-weighted approval odds and near-term catalysts (FDA meeting, BLA timing) based on the reported survival benefit and the magnitude of the market reaction.

03

What to watch

The article notes further analysis and future conference/publication; traders may need to wait for secondary endpoint clarity, subgroup consistency, and any manufacturing or CMC considerations ahead of the accelerated filing discussion.

Relevance 9/10Novelty 9/10Timing: same-day reaction to phase 3 pivotal trial results

Background

Sellas is developing galinpepimut-S (GPS) for acute myeloid leukemia patients in second or later remission who cannot undergo stem-cell transplant.

Company-level read

Ticker impact

$SLSBullishHigh confidence
Context

Sellas Life Sciences shares surged after its phase 3 REGAL trial met the primary goal, cutting AML death risk by 41% versus control.

Expected impact

Likely further upside pressure as traders price in accelerated regulatory progress, tempered by skepticism around investigational status and pending conference/publication details.

Evidence & confidence

The article reports statistically significant phase 3 survival benefit, a large same-day move, and explicit next regulatory steps (FDA meeting and BLA prep), which are direct catalysts for valuation and positioning.

Market effects

Reinforces risk appetite for AML and oncology vaccine platforms, potentially lifting sentiment for adjacent late-stage biotech programs.

Primarily US biotech sentiment, with Nasdaq small/mid-cap momentum effects from a large single-name surge.

Limited direct global spillover beyond oncology investor sentiment, unless follow-on conference/publication details shift broader expectations.

Counterpoint

Even with positive phase 3 survival, investors may over-discount regulatory risk; FDA could require additional evidence or question endpoint robustness, leading to post-pop mean reversion.

Key entities

  • Sellas Life Sciences Group

    Nasdaq-listed biotech whose phase 3 REGAL trial results drove a sharp share-price surge.

  • Galinpepimut-S (GPS)

    Experimental cancer vaccine evaluated in the phase 3 REGAL study.

  • US Food and Drug Administration (FDA)

    Regulatory body Sellas plans to meet to discuss an accelerated regulatory filing strategy.

Related articles

$NVDAMedAI 8/10

Futures Rise As Huang-less Nvidia Beats And Raises, Gold Crashes Below $3,800

US futures rise as Nvidia (NVDA) reports strong earnings and raises guidance, boosting AI-related stocks. Gold drops below $3,800 after Fed Governor Waller's comments. Nvidia's Q4 revenue guidance is $130B vs. estimates of $125B. Premarket movers include TSLA, GOOGL, AMZN, AAPL, META, AVGO, CRWV, AAOI, BLSH, DLB, LOW, SLS, TTWO, TNDM. Fed policy and economic data releases are in focus.

$SLSHighAI 9/10

SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here

Sellas Life Sciences (SLS) reported positive Phase 3 trial results for its cancer vaccine, Galinpepimut-S (GPS), showing a 24-month median survival vs. 14.7 months in the control group. The company plans to meet with the FDA and aims to file for approval in early 2027. SLS also announced a $150M share offering to fund further development. Analysts and investors reacted positively, with some noting potential for expedited approval and broader applications.

$SLSHighAI 9/10

SLS Joins MRNA And ANL In Biotech’s Top 3 Winners This Year — Can Sellas Deliver Another Double From Here?

Sellas Life Sciences (SLS) stock surged 156% to $19.15 after positive Phase 3 trial results for its leukemia vaccine, Galinpepimut-S. The trial showed a 41% reduction in death risk, with median survival of 24 months vs. 14.7 months in the control group. Maxim Group raised its price target to $40, citing significant upside potential. SLS is planning a $150M share offering to fund further development.

$SLSMedAI 8/10

SELLAS shares jump 157% after company says its leukemia

SELLAS Life Sciences (SLS) shares surged 157% after reporting positive Phase 3 trial results for its leukemia vaccine, galinpepimut-S, showing a 41% reduction in death risk. The stock closed at $19.17, valuing the company at $3.9B. However, after launching a $150M stock offering, shares dropped 10-13% in after-hours trading. The trial enrolled 126 patients, with median survival of 24.0 months vs. 14.7 months for existing treatments. The company plans to file for regulatory approval in 2027.